TOI (The Oncology Institute) Inventories, Finished Goods: $24.3 Mil (As of Mar. 2026)


TOI The Oncology Institute Inc TOI
56 GF Score
Price $5.28
GF Value $2.25
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is The Oncology Institute Inventories, Finished Goods?

The Oncology Institute TOI -4.17% 56 Inventories, Finished Goods is $24.3 Mil as of Mar. 2026. GuruFocus rates TOI with a GF Score™ of 56/100 and a GF Value™ of $2.25 (Significantly Overvalued). The stock has 6 warning signs investors should review.

The Oncology Institute's quarterly finished goods declined from Sep. 2025 ($18.9 Mil) to Dec. 2025 ($16.9 Mil) but then increased from Dec. 2025 ($16.9 Mil) to Mar. 2026 ($24.3 Mil).

The Oncology Institute's annual finished goods declined from Dec. 2023 ($13.7 Mil) to Dec. 2024 ($10.0 Mil) but then increased from Dec. 2024 ($10.0 Mil) to Dec. 2025 ($16.9 Mil).

The Oncology Institute Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for The Oncology Institute's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The Oncology Institute Inventories, Finished Goods Chart

The Oncology Institute Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial 6.44 9.26 13.68 10.04 16.88

The Oncology Institute Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.31 15.79 18.88 16.88 24.29
TOI
56GF Score
The Oncology Institute Inc TOI
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

The Oncology Institute Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of $24.3 Mil mean?
The Oncology Institute (TOI) has a Inventories, Finished Goods of $24.3 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on The Oncology Institute and its competitors.
Is The Oncology Institute's Inventories, Finished Goods too high?
The Oncology Institute's current Inventories, Finished Goods is $24.3 Mil. Overall, The Oncology Institute has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does The Oncology Institute's Inventories, Finished Goods compare to CYH and SRTA?
The Oncology Institute's Inventories, Finished Goods of $24.3 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Healthcare Providers & Services company?
A good Inventories, Finished Goods depends on the Healthcare Providers & Services industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on The Oncology Institute and its competitors. The Oncology Institute's current Inventories, Finished Goods is $24.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Oncology Institute stock overvalued right now?
Based on GuruFocus' analysis, The Oncology Institute (TOI) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.25, compared to a current price of $5.28 — trading 134.7% above its estimated fair value. The current Inventories, Finished Goods is $24.3 Mil. The Oncology Institute's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For The Oncology Institute (TOI), the current Inventories, Finished Goods is $24.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is The Oncology Institute (TOI) Overvalued in 2026?

Based on GuruFocus' analysis, The Oncology Institute stock appears to be overvalued. The current stock price of $5.28 is trading 134.7% above its estimated GF Value™ of $2.25. GuruFocus considers The Oncology Institute to be Significantly Overvalued.

Key valuation signals for TOI:

  • Inventories, Finished Goods: $24.3 Mil
  • GF Value™: $2.25 vs. price of $5.28 (134.7% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the TOI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

The Oncology Institute Business Description

Address 18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score

Get the complete analysis for TOI

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.28
Price
$2.25
GF Value